Results of European post-marketing surveillance of bosentan in pulmonary hypertension

After the approval of bosentan for the treatment of pulmonary arterial hypertension (PAH), European authorities required the introduction of a post-marketing surveillance system (PMS) to obtain further data on its safety profile. A novel, prospective, internet-based PMS was designed, which solicited...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The European respiratory journal 2007-08, Vol.30 (2), p.338-344
Hauptverfasser:	Humbert, M, Segal, E. S, Kiely, D. G, Carlsen, J, Schwierin, B, Hoeper, M. M
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse Drug Reaction Reporting Systems Antihypertensive Agents - adverse effects Biological and medical sciences Europe Humans Hypertension, Pulmonary - drug therapy Internet Medical sciences Pneumology Product Surveillance, Postmarketing Prospective Studies Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases Sulfonamides - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!